I型干扰素在系统性红斑狼疮中的研究进展  

Research Progress of Type I Interferon in Systemic Lupus Erythematosus

作　　者：孙颖颖 宋芹[2] 

机构地区：[1]济宁医学院临床医学院,山东 济宁 [2]济宁医学院附属医院风湿免疫科,山东 济宁

出　　处：《临床个性化医学》2024年第4期1573-1579,共7页Journal of Clinical Personalized Medicine

基　　金：基于转录组数据的系统性红斑狼疮疾病机制及治疗的研究(2021YXNS091);ANCA相关性血管炎肺受累风险因素分析及预测模型建立(20230YXNS154);白芍总苷治疗类风湿关节炎合并冠心病的疗效观察及作用机制研究(2022YXNS185)。

摘　　要：系统性红斑狼疮(SLE)是一种慢性、多系统、炎症性自身免疫性疾病,具有复杂的发病机制和遗传易感性。随着对这种疾病的不断了解,发现SLE与干扰素基因特征有关,尤其I型干扰素对先天免疫系统和适应性免疫系统都有影响,本文就I型干扰素在系统性红斑狼疮中的研究进展进行综述。Systemic lupus erythematosus (SLE) is a chronic, multisystem, inflammatory autoimmune disease with complex pathogenesis and genetic susceptibility. With the increasing understanding of this disease, it has been found that SLE is associated with interferon gene characterization, especially type I interferon, which has an effect on both the innate and adaptive immune systems, and this article provides a review of the progress of type I interferon research in SLE.

关 键 词：系统性狼疮狼疮 I型干扰素 干扰素-Α 干扰素-Β 干扰素-κ 治疗靶点 

分 类 号：R59[医药卫生—内科学]